The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s biologics testing market report forecasts the biologics testing market size to grow to $9.24 Billion by 2027, with a CAGR (compound annual growth rate) of more than 16%.

Learn More On The Biologics Testing Market Report 2023 – https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Biologics Testing Market Size Forecast
The global biologics testing market is expected to grow from $4.42 billion in 2022 to $5.09 billion in 2023 at a compound annual growth rate (CAGR) of 15.13%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global biologics testing market size is expected to reach $9.24 billion in 2027 at a CAGR of 16.09%.

North America held the largest biologics testing market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Biologics Testing Market Driver ­– Growth In Pharmaceutical And Biotechnology Industries
According to the European Federation of Pharmaceutical Industries and Associations, a trade association and lobbying organisation based in Brussels, European pharmaceutical production increased by 4.64% in June 2022, from € 286,697 million ($307,416 million) in 2020 to € 300,000 million ($321,681 million) in 2021. Furthermore, according to Torys LLP, a corporate law firm based in Canada, 84 initial public offerings for biotech businesses in the United States in 2020 raised a total of US$15 billion. As a result, the rapidly expanding pharmaceutical and biotechnology sectors are propelling the biologics testing market forward.

Request for A Sample Of The Global Biologics Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10276&type=smp

Key Biologics Testing Market Trend – Product Innovations
Companies in the biologics testing industry are implementing new creative products to maintain their market position. For example, Charles River Laboratories International, Inc., a non-clinical contract research organisation based in the United States, will unveil the Endosafe® Nexus 200TM, a new addition to its extensive endotoxin testing line, in December 2022. The Nexus 200 is a completely robotic, data integrity compliant instrument that represents the next level in Charles River’s progress. It employs Endosafe Limulus Amebocyte Lysate (LAL) cartridge technology and is capable of handling simple or complex serial dilutions for water, in-process, and final product testing. The system, which is based on Endosafe EndoScan-V version 6.1, allows data to be exported into a LIMS interface and provides increased traceability, security, and data management.

Biologics Testing Market Segment
1) By Product: Reagents And Kits, Instruments, Other Products
2) By Test Type: Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-Cell Proteins And DNA Detection Tests, Virus Safety Test, Other Test Types
3) By Application: Vaccine Development And Manufacturing, Monoclonal Antibodies Development And Manufacturing, Cellular And Gene Therapy Products Development And Manufacturing, Blood And Blood Products Development And Manufacturing, Other Applications

Biologics Testing Market Major Players and Strategies
Major players in the biologics testing market are Charles River Laboratories Inc., Thermo Fisher Scientific Inc., Merck KGaA, SGS Société Générale de Surveillance SA, WuXi AppTec Co Ltd., Sartorius AG, Cytovance Biologics Inc., Pace Analytical Services Inc., Avance Biosciences, Eurofins Scientific, Biomerieux SA, Lonza Group Ltd., Genscript Biotech Corp, Bio-Rad Laboratories Inc. and Accugen Laboratories Inc.

PPD Inc. was acquired for $17.4 billion by Thermo Fisher Scientific, a biotechnology firm based in the United States, in December 2021. This acquisition is expected to help Thermo Fisher become a market leader in clinical research services and to broaden the company’s offering. It would bring a solid drug development platform, patient enrollment experience, and laboratory capabilities. PPD Inc. is a contract research organisation established in the United States that offers full, integrated drug development, laboratory, and lifecycle management services.

The Biologics Testing Global Market Report 2023 covers regional data on biologics testing market size, biologics testing market trends and drivers, opportunities, strategies, and biologics testing market competitor analysis. The countries covered in the biologics testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Biologics testing often includes a variety of services targeted at determining the safety, efficacy, and quality of biological goods.

View More Reports Related To The Biologics Testing Market –
Biologics Global Market Report 2023
Testing, Inspection, And Certification Global Market Report 2023
Testing Software Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: